Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc. Show more
5005 McConnell Avenue, Los Angeles, CA, 90066, United States
Start AI Chat
Market Cap
347.3M
52 Wk Range
$0.90 - $16.34
Previous Close
$9.54
Open
$9.85
Volume
149,465
Day Range
$9.68 - $11.90
Enterprise Value
250.8M
Cash
14.76M
Avg Qtr Burn
-4.298M
Insider Ownership
69.12%
Institutional Own.
3.41%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
AP-SA02 Details Bacterial infection | Phase 3 Initiation | |
AP-PA02 Details Non-Cystic Fibrosis Bronchiectasis | Phase 2 Update | |
AP-PA02 Details Cystic fibrosis | Phase 1/2 Update |
